Related Experiment Video
Updated: Aug 20, 2025
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Identification of Potential Biomarkers for Cancer Cachexia and Anti-Fn14 Therapy
Zhipeng Cao1,2, Ingrid J Burvenich2, Kening Zhao1,3
1Department of Biochemistry and Genetics, La Trobe University, Melbourne, VIC 3086, Australia.
Background:
Developing therapies for cancer cachexia has not been successful to date, in part due to the challenges of achieving robust quantitative measures as a readout of patient treatment. Hence, identifying biomarkers to assess the outcomes of treatments for cancer cachexia is of great interest and important for accelerating future clinical trials.
Methods:
We established a novel xenograft model for cancer cachexia with a cachectic human PC3* cell line, which was responsive to anti-Fn14 mAb treatment. Using RNA-seq and secretomic analysis, genes differentially expressed in cachectic and non-cachectic tumors were identified and validated by digital droplet PCR (ddPCR). Correlation analysis was performed to investigate their impact on survival in cancer patients.
Results:
A total of 46 genes were highly expressed in cachectic PC3* tumors, which were downregulated by anti-Fn14 mAb treatment. High expression of the top 10 candidates was correlated with low survival and high cachexia risk in different cancer types. Elevated levels of LCN2 were observed in serum samples from cachectic patients compared with non-cachectic cancer patients.
Conclusion:
The top 10 candidates identified in this study are candidates as potential biomarkers for cancer cachexia. The diagnostic value of LCN2 in detecting cancer cachexia is confirmed in patient samples.
Insights
Identifying novel biomarkers for cancer cachexia is crucial for treatment development. This study highlights 10 candidate genes and confirms LCN2
Area of Science:
- Oncology
- Biomarker Discovery
- Cancer Cachexia Research
Background:
- Therapeutic development for cancer cachexia is hindered by a lack of reliable quantitative outcome measures.
- Identifying robust biomarkers is essential for accelerating clinical trials and evaluating treatment efficacy.
Purpose of the Study:
- To identify and validate potential biomarkers for cancer cachexia.
- To assess the diagnostic value of candidate biomarkers in patient samples.
Main Methods:
- Development of a novel xenograft model for cancer cachexia using PC3* cells.
- RNA-sequencing and secretomic analysis to identify differentially expressed genes.
- Digital droplet PCR (ddPCR) for gene validation and correlation analysis with patient survival.
Main Results:
- 46 highly expressed genes in cachectic tumors were identified, with 10 candidates showing correlation with poor survival and high cachexia risk.
- Downregulation of these genes was observed following anti-Fn14 mAb treatment.
- Elevated serum LCN2 levels were detected in cachectic patients compared to non-cachectic controls.
Conclusions:
- The top 10 identified genes represent promising candidates for cancer cachexia biomarkers.
- LCN2 demonstrates diagnostic value for detecting cancer cachexia in patient serum samples.
